NuCana (FRA:N040) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:N040 NuCana PLC FRA:N040
30 GF Score
Price €3.20
! 2 Warning Signs
View Full Analysis

What is NuCana Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:N040
30GF Score
NuCana PLC FRA:N040
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NuCana Business Description

Other Exchanges NCNA:USA
Address 3 Lochside Way, Edinburgh, GBR, EH12 9DT
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
30GF Score

Get the complete analysis for FRA:N040

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.20
Price